Logo

Guerbet and Bracco Received Positive Opinion from EU’s CHMP for Elucirem & Vueway (Gadopiclenol)

Share this

Guerbet and Bracco Received Positive Opinion from EU’s CHMP for Elucirem & Vueway (Gadopiclenol)

Shots:

  • The positive opinion was adopted based on 2 P-III Clinical trials (PICTURE) & (PROMISE) evaluating efficacy & safety for Elucirem & Vueway, MRI with contrast enhancement in adults & children aged 2yrs. & over 
  • The result of the study demonstrated thatGadopiclenol  provided non-inferior outcomes in brain & whole body. The evaluation criteria were met with Gadopiclenol (0.05 mmol/kg) injection which includes the superiority of using a contrast product in an examination over one without & the non-inferiority of Gadopiclenol (0.05 mmol/kg) vs Gadobutrol (0.1 mmol/kg)
  • Gadopiclenol is a novel macrocyclic gadolinium-based contrast agent (GBCA) with excellent relaxivity. Its efficacy and safety have been assessed in MRI scans of the musculoskeletal system, head, neck, thorax, abdomen, and pelvis

Ref: Guerbet | Image:  Guerbet

Related News:- Guerbet’s Elucirem (gadopiclenol) Receives the US FDA’s Approval for Contrast-Enhanced Magnetic Resonance Imaging

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions